Chantal Sauvageau completed her Doctorate in Medicine at Laval University in 1999, and obtained a Master’s degree in Community Health from the same University in 2002. She then completed her specialty training and obtained her certificate of specialist in Community Health from the Collège des médecins du Québec and the Royal College of Physicians and Surgeons of Canada, in 2004. She is a consultant in infectious diseases at the National Institute of Public Health of Quebec, and the Regional Directorate of Public Health of the national capital. She is a researcher in the Immunization Research Team of the Research Centre of the CHU de Québec, and an Associate Professor in the Faculty of Medicine at Laval University. She has been an active member of the Committee on Immunization of Quebec (CIQ) since 2008. She is also a member of the shingles working group as well as of the HPV working group of the National Advisory Committee on Immunization (NACI). In 2013, she participated in the work of the World Health Organization (WHO), leading to a WHO recommendation on the use of a 2-dose vaccination schedule for HPV vaccine.
Evaluate the impact of HPV vaccination and the vaccination against chickenpox and shingles
Her main research papers focus on HPV vaccination, particularly on the evaluation of the immunogenicity and efficacy of available vaccines, on the impact of varicella and shingles vaccination, on the training of healthcare professionals on immunization, and the problem of vaccine delays. More specifically, by conducting clinical trials, her projects aim to know the immune response to vaccines: duration of protection, decrease in antibody levels, impact of interactions and co-administration of vaccines on the immune response, effect of a booster dose, etc. Among other things, she is the co-principal investigator of a randomized clinical trial named ICI-HPV, having recruited 3,300 14-16 year old girls from 2013 to 2016, who are followed for 5 years. The trial aims to evaluate the effectiveness of a 2-dose schedule of HPV vaccination, 10 years after receiving the first dose of vaccine at an age of 9 or 10.
She also collaborates on projects related to the modeling and analysis of the cost-effectiveness of planned or implemented vaccination programs, as well as on studies related to the acceptability of implemented vaccination programs, by measuring the immunization coverage rate, as well as the perception of health professionals and of the population.
Canada G1E 7G9
Data not available
Challenges and opportunities of school-based HPV vaccination in Canada.Journal Article
Hum Vaccin Immunother, 2019.
Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada.Journal Article
BMC Public Health, 18 (1), pp. 1364, 2018.
Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.Journal Article
Vaccine, 36 (46), pp. 7017-7024, 2018, ISSN: 0264-410X.
Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.Journal Article
Hum Vaccin Immunother, pp. 1-5, 2018.
Overview of knowledge, attitudes, beliefs, vaccine hesitancy and vaccine acceptance among mothers of infants in Quebec, Canada.Journal Article
Hum Vaccin Immunother, pp. 1-8, 2018.
- Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Interchangeabilité des vaccins VPH., Subvention, Ministère de la Santé et des Services sociaux, from 2011-03-29 to 2019-12-31
Recently finished projects
- ICI-VPH: IMpact des calendriers d'immunisation contre les VPH, Subvention, Ministère de la Santé et des Services sociaux, from 2013-05-01 to 2017-04-30